01 / DESIGN
What was studied?
The trial randomized 579 adults who had already lost at least 5% of body weight during a 12-week intensive lifestyle program. It compared tirzepatide with placebo for another 72 weeks.
02 / FINDINGS
What did the researchers report?
Participants assigned tirzepatide had additional average weight reduction, while the placebo group gained some weight from randomization. Gastrointestinal events were the most common adverse effects.
03 / LIMITS
How should it be interpreted?
The participants were selected for an initial response to lifestyle intervention. Their results do not represent every person beginning weight management, and the study does not validate unsupervised use of a research material.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.